Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
Giorgia RengaEmilia NunziMarilena ParianoMatteo PuccettiMarina Maria BelletGiuseppe PieracciniFiorella D'OnofrioIlaria SantarelliClaudia StincardiniFranco AversaFrancesca RiuzziCinzia AntognelliMarco GargaroOxana BereshchenkoMaurizio RicciStefano GiovagnoliLuigina RomaniClaudio CostantiniPublished in: Journal for immunotherapy of cancer (2022)
This study provides a proof-of-concept demonstration that moving past bacterial phylogeny and focusing on bacterial metabolome may lead to a new class of discrete molecules, and that working at the interface between microbes and the host immune system may optimize ICI therapy.